The tweet was deleted by the author.
But we saved everything 🙂.
CVRx is set to present a session titled Barostim: Flipping the Parasympathetic Switch at the upcoming ISHLT2026 conference.
The session will focus on how Barostim technology complements guideline-directed medical therapy (GDMT) by targeting neurohormonal mechanisms involved in heart failure. Leading physicians Dr. Peter Eckman, Dr. Shelley Hall, and Dr. Matthew Danter will participate as expert faculty, offering in-depth discussion on Barostim and its applications in clinical practice.
CVRx recently presented Barostim device therapy at ACC26, highlighting its potential to improve exercise capacity for heart failure patients beyond standard GDMT at the event. The company is also projecting preliminary first-quarter 2026 revenue of $14.7 to $14.8 million, an estimated 20 percent increase from the prior year according to its forecast. Both developments reflect ongoing efforts to advance Barostim's role in clinical care and drive business growth.